Cargando…
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degenerati...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346122/ https://www.ncbi.nlm.nih.gov/pubmed/25733984 http://dx.doi.org/10.1186/s13195-014-0093-y |
_version_ | 1782359689066971136 |
---|---|
author | Sha, Sharon J Ghosh, Pia M Lee, Suzee E Corbetta-Rastelli, Chiara Jagust, Willian J Kornak, John Rankin, Katherine P Grinberg, Lea T Vinters, Harry V Mendez, Mario F Dickson, Dennis W Seeley, William W Gorno-Tempini, Marilu Kramer, Joel Miller, Bruce L Boxer, Adam L Rabinovici, Gil D |
author_facet | Sha, Sharon J Ghosh, Pia M Lee, Suzee E Corbetta-Rastelli, Chiara Jagust, Willian J Kornak, John Rankin, Katherine P Grinberg, Lea T Vinters, Harry V Mendez, Mario F Dickson, Dennis W Seeley, William W Gorno-Tempini, Marilu Kramer, Joel Miller, Bruce L Boxer, Adam L Rabinovici, Gil D |
author_sort | Sha, Sharon J |
collection | PubMed |
description | INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these features in predicting underlying AD pathology in individual patients is unknown. The goal of this study is to evaluate the utility of modified clinical criteria and visual interpretations of magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) for predicting amyloid deposition (as a surrogate of Alzheimer’s disease neuropathology) in patients presenting with CBS. METHODS: In total, 25 patients meeting CBS core criteria underwent amyloid (Pittsburgh compound B; PIB) PET scans. Clinical records, MRI, and FDG scans were reviewed blinded to PIB results. Modified clinical criteria were used to classify CBS patients as temporoparietal variant CBS (tpvCBS) or frontal variant CBS (fvCBS). MRI and FDG-PET were classified based on the predominant atrophy/hypometabolism pattern (frontal or temporoparietal). RESULTS: A total of 9 out of 13 patients classified as tpvCBS were PIB+, compared to 2out of 12 patients classified as fvCBS (P < 0.01, sensitivity 82%, specificity 71% for PIB+ status). Visual MRI reads had 73% sensitivity and 46% specificity for PIB+ status with moderate intra-rater reliability (Cohen’s kappa = 0.42). Visual FDG reads had higher sensitivity (91%) for PIB+ status with perfect intra-rater reliability (kappa = 1.00), though specificity was low (50%). PIB results were confirmed in all 8 patients with available histopathology (3 PIB+ with confirmed AD, 5 PIB- with FTLD). CONCLUSIONS: Splitting CBS patients into frontal or temporoparietal clinical variants can help predict the likelihood of underlying AD, but criteria require further refinement. Temporoparietal-predominant neuroimaging patterns are sensitive but not specific for AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-014-0093-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4346122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43461222015-03-03 Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography Sha, Sharon J Ghosh, Pia M Lee, Suzee E Corbetta-Rastelli, Chiara Jagust, Willian J Kornak, John Rankin, Katherine P Grinberg, Lea T Vinters, Harry V Mendez, Mario F Dickson, Dennis W Seeley, William W Gorno-Tempini, Marilu Kramer, Joel Miller, Bruce L Boxer, Adam L Rabinovici, Gil D Alzheimers Res Ther Research INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these features in predicting underlying AD pathology in individual patients is unknown. The goal of this study is to evaluate the utility of modified clinical criteria and visual interpretations of magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) for predicting amyloid deposition (as a surrogate of Alzheimer’s disease neuropathology) in patients presenting with CBS. METHODS: In total, 25 patients meeting CBS core criteria underwent amyloid (Pittsburgh compound B; PIB) PET scans. Clinical records, MRI, and FDG scans were reviewed blinded to PIB results. Modified clinical criteria were used to classify CBS patients as temporoparietal variant CBS (tpvCBS) or frontal variant CBS (fvCBS). MRI and FDG-PET were classified based on the predominant atrophy/hypometabolism pattern (frontal or temporoparietal). RESULTS: A total of 9 out of 13 patients classified as tpvCBS were PIB+, compared to 2out of 12 patients classified as fvCBS (P < 0.01, sensitivity 82%, specificity 71% for PIB+ status). Visual MRI reads had 73% sensitivity and 46% specificity for PIB+ status with moderate intra-rater reliability (Cohen’s kappa = 0.42). Visual FDG reads had higher sensitivity (91%) for PIB+ status with perfect intra-rater reliability (kappa = 1.00), though specificity was low (50%). PIB results were confirmed in all 8 patients with available histopathology (3 PIB+ with confirmed AD, 5 PIB- with FTLD). CONCLUSIONS: Splitting CBS patients into frontal or temporoparietal clinical variants can help predict the likelihood of underlying AD, but criteria require further refinement. Temporoparietal-predominant neuroimaging patterns are sensitive but not specific for AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-014-0093-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-02 /pmc/articles/PMC4346122/ /pubmed/25733984 http://dx.doi.org/10.1186/s13195-014-0093-y Text en © Sha et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sha, Sharon J Ghosh, Pia M Lee, Suzee E Corbetta-Rastelli, Chiara Jagust, Willian J Kornak, John Rankin, Katherine P Grinberg, Lea T Vinters, Harry V Mendez, Mario F Dickson, Dennis W Seeley, William W Gorno-Tempini, Marilu Kramer, Joel Miller, Bruce L Boxer, Adam L Rabinovici, Gil D Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title | Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title_full | Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title_fullStr | Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title_full_unstemmed | Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title_short | Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
title_sort | predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346122/ https://www.ncbi.nlm.nih.gov/pubmed/25733984 http://dx.doi.org/10.1186/s13195-014-0093-y |
work_keys_str_mv | AT shasharonj predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT ghoshpiam predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT leesuzeee predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT corbettarastellichiara predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT jagustwillianj predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT kornakjohn predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT rankinkatherinep predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT grinbergleat predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT vintersharryv predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT mendezmariof predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT dicksondennisw predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT seeleywilliamw predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT gornotempinimarilu predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT kramerjoel predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT millerbrucel predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT boxeradaml predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography AT rabinovicigild predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography |